A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium

Anindita Mukerjee, Pinar Iyidogan, Alejandro Castellanos, José A. Cisneros, Daniel Czyzyk, Amalendu Prakash Ranjan, William L. Jorgensen, A. Clinton White, Jamboor K. Vishwanatha, Karen S. Anderson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cryptosporidiosis, a gastrointestinal disease caused by protozoans of the genus Cryptosporidium, is a common cause of diarrheal diseases and often fatal in immunocompromised individuals. Bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) from Cryptosporidium hominis (C. hominis) has been a molecular target for inhibitor design. C. hominis TS-DHFR inhibitors with nM potency at a biochemical level have been developed however drug delivery to achieve comparable antiparasitic activity in Cryptosporidium infected cell culture has been a major hurdle for designing effective therapies. Previous mechanistic and structural studies have identified compound 906 as a nM C. hominis TS-DHFR inhibitor in vitro, having μM antiparasitic activity in cell culture. In this work, proof of concept studies are presented using a nanotherapy approach to improve drug delivery and the antiparasitic activity of 906 in cell culture. We utilized PLGA nanoparticles that were loaded with 906 (NP-906) and conjugated with antibodies to the Cryptosporidium specific protein, CP2, on the nanoparticle surface in order to specifically target the parasite. Our results indicate that CP2 labeled NP-906 (CP2-NP-906) reduces the level of parasites by 200-fold in cell culture, while NP-906 resulted in 4.4-fold decrease. Moreover, the anticryptosporidial potency of 906 improved 15 to 78-fold confirming the utility of the antibody conjugated nanoparticles as an effective drug delivery strategy.

Original languageEnglish (US)
Pages (from-to)2065-2067
Number of pages3
JournalBioorganic and Medicinal Chemistry Letters
Volume25
Issue number10
DOIs
StatePublished - Jun 15 2015

Fingerprint

Cryptosporidium
Cell culture
Antiparasitic Agents
Drug delivery
Folic Acid Antagonists
Cell Culture Techniques
Nanoparticles
Antibodies
Parasites
Cryptosporidiosis
Gastrointestinal Diseases
Pharmaceutical Preparations
thymidylate synthase-dihydrofolate reductase
Proteins

Keywords

  • Cryptosporidium hominis
  • Dihydrofolate reductase
  • Drug delivery
  • Nanoparticle
  • Thymidylate synthase

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium. / Mukerjee, Anindita; Iyidogan, Pinar; Castellanos, Alejandro; Cisneros, José A.; Czyzyk, Daniel; Ranjan, Amalendu Prakash; Jorgensen, William L.; White, A. Clinton; Vishwanatha, Jamboor K.; Anderson, Karen S.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 25, No. 10, 15.06.2015, p. 2065-2067.

Research output: Contribution to journalArticle

Mukerjee, Anindita ; Iyidogan, Pinar ; Castellanos, Alejandro ; Cisneros, José A. ; Czyzyk, Daniel ; Ranjan, Amalendu Prakash ; Jorgensen, William L. ; White, A. Clinton ; Vishwanatha, Jamboor K. ; Anderson, Karen S. / A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium. In: Bioorganic and Medicinal Chemistry Letters. 2015 ; Vol. 25, No. 10. pp. 2065-2067.
@article{f54bdbdbcb514ee9a74230a4da3683b9,
title = "A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium",
abstract = "Cryptosporidiosis, a gastrointestinal disease caused by protozoans of the genus Cryptosporidium, is a common cause of diarrheal diseases and often fatal in immunocompromised individuals. Bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) from Cryptosporidium hominis (C. hominis) has been a molecular target for inhibitor design. C. hominis TS-DHFR inhibitors with nM potency at a biochemical level have been developed however drug delivery to achieve comparable antiparasitic activity in Cryptosporidium infected cell culture has been a major hurdle for designing effective therapies. Previous mechanistic and structural studies have identified compound 906 as a nM C. hominis TS-DHFR inhibitor in vitro, having μM antiparasitic activity in cell culture. In this work, proof of concept studies are presented using a nanotherapy approach to improve drug delivery and the antiparasitic activity of 906 in cell culture. We utilized PLGA nanoparticles that were loaded with 906 (NP-906) and conjugated with antibodies to the Cryptosporidium specific protein, CP2, on the nanoparticle surface in order to specifically target the parasite. Our results indicate that CP2 labeled NP-906 (CP2-NP-906) reduces the level of parasites by 200-fold in cell culture, while NP-906 resulted in 4.4-fold decrease. Moreover, the anticryptosporidial potency of 906 improved 15 to 78-fold confirming the utility of the antibody conjugated nanoparticles as an effective drug delivery strategy.",
keywords = "Cryptosporidium hominis, Dihydrofolate reductase, Drug delivery, Nanoparticle, Thymidylate synthase",
author = "Anindita Mukerjee and Pinar Iyidogan and Alejandro Castellanos and Cisneros, {Jos{\'e} A.} and Daniel Czyzyk and Ranjan, {Amalendu Prakash} and Jorgensen, {William L.} and White, {A. Clinton} and Vishwanatha, {Jamboor K.} and Anderson, {Karen S.}",
year = "2015",
month = "6",
day = "15",
doi = "10.1016/j.bmcl.2015.03.091",
language = "English (US)",
volume = "25",
pages = "2065--2067",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium

AU - Mukerjee, Anindita

AU - Iyidogan, Pinar

AU - Castellanos, Alejandro

AU - Cisneros, José A.

AU - Czyzyk, Daniel

AU - Ranjan, Amalendu Prakash

AU - Jorgensen, William L.

AU - White, A. Clinton

AU - Vishwanatha, Jamboor K.

AU - Anderson, Karen S.

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Cryptosporidiosis, a gastrointestinal disease caused by protozoans of the genus Cryptosporidium, is a common cause of diarrheal diseases and often fatal in immunocompromised individuals. Bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) from Cryptosporidium hominis (C. hominis) has been a molecular target for inhibitor design. C. hominis TS-DHFR inhibitors with nM potency at a biochemical level have been developed however drug delivery to achieve comparable antiparasitic activity in Cryptosporidium infected cell culture has been a major hurdle for designing effective therapies. Previous mechanistic and structural studies have identified compound 906 as a nM C. hominis TS-DHFR inhibitor in vitro, having μM antiparasitic activity in cell culture. In this work, proof of concept studies are presented using a nanotherapy approach to improve drug delivery and the antiparasitic activity of 906 in cell culture. We utilized PLGA nanoparticles that were loaded with 906 (NP-906) and conjugated with antibodies to the Cryptosporidium specific protein, CP2, on the nanoparticle surface in order to specifically target the parasite. Our results indicate that CP2 labeled NP-906 (CP2-NP-906) reduces the level of parasites by 200-fold in cell culture, while NP-906 resulted in 4.4-fold decrease. Moreover, the anticryptosporidial potency of 906 improved 15 to 78-fold confirming the utility of the antibody conjugated nanoparticles as an effective drug delivery strategy.

AB - Cryptosporidiosis, a gastrointestinal disease caused by protozoans of the genus Cryptosporidium, is a common cause of diarrheal diseases and often fatal in immunocompromised individuals. Bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) from Cryptosporidium hominis (C. hominis) has been a molecular target for inhibitor design. C. hominis TS-DHFR inhibitors with nM potency at a biochemical level have been developed however drug delivery to achieve comparable antiparasitic activity in Cryptosporidium infected cell culture has been a major hurdle for designing effective therapies. Previous mechanistic and structural studies have identified compound 906 as a nM C. hominis TS-DHFR inhibitor in vitro, having μM antiparasitic activity in cell culture. In this work, proof of concept studies are presented using a nanotherapy approach to improve drug delivery and the antiparasitic activity of 906 in cell culture. We utilized PLGA nanoparticles that were loaded with 906 (NP-906) and conjugated with antibodies to the Cryptosporidium specific protein, CP2, on the nanoparticle surface in order to specifically target the parasite. Our results indicate that CP2 labeled NP-906 (CP2-NP-906) reduces the level of parasites by 200-fold in cell culture, while NP-906 resulted in 4.4-fold decrease. Moreover, the anticryptosporidial potency of 906 improved 15 to 78-fold confirming the utility of the antibody conjugated nanoparticles as an effective drug delivery strategy.

KW - Cryptosporidium hominis

KW - Dihydrofolate reductase

KW - Drug delivery

KW - Nanoparticle

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=84937763193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937763193&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2015.03.091

DO - 10.1016/j.bmcl.2015.03.091

M3 - Article

VL - 25

SP - 2065

EP - 2067

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 10

ER -